Organoid Cultures Derived from Patients with Advanced Prostate Cancer
CopyNumberAnalysis
Array-CGHusingtheAgilentSurePrintG31Mmicroarraywasperformedusingmanufacturer’sinstructionsbytheMSKCCgenomicscorefacility.WeusedeitherPromegapool’smaleDNAorpatientnormalDNAasthehybridizationcontrol.SegmentationanddiscretecopynumbercallswasperformedusingwithCircularBinarySegmentation(Tayloretal.,2010).WeuploadedpriorAgilent244AArrayCGHdataofexistingprostatecancercelllinesfromNCBIGeneExpressionOmnibus(GSE21032)foranalysis(22RV1,DU145,LAPC4,LNCaP,PC3,andVCAP)(Tayloretal.,2010).Datawasmappedtohumangenomereferencesequence(GRC37/hg19).RepresentativeregionsaredisplayedusingIntegratedGenomicsViewer(IGV).
Whole-ExomeSequencingandDataAnalysis
TheDNAlibraryofthesampleswaspreparedaccordingtotheAgilentSureSelectXT2TargetEnrichmentSystem,whichcoversabout51Mbofgenomicregionscorrespondingtoproteincodinggenesusing1mginputDNA.
Paired-endsequencing(2375bp)wasthenperformedusingIlluminaHiSeq2500.Samplesweremultiplexed(2samplesperlane)toensureanominalcoverageof 2503persample.Rawsequenceswerealignedtothehumangenomereferencesequence(GRC37/hg19)usingBWA(LiandDurbin,2010).Weattainedameanofaveragecoverageof 1423acrosssampleswithallsamplesshowingmorethan1003averagecoverageinthecapturedregions(range103–178).Onaverage,about91%ofcapturedbaseswerecoveredat>103(TableS1).WethenappliedGATKbasequalityscorerecali-bration,indelrealignment,duplicateremovaltoremovepotentialartifactsandincreasethequalityofthealignment(McKennaetal.,2010).
Single-nucleotidevariantcallswereperformedusinganin-housecomputa-tionaltoolviathecomparisonofthetumorororganoid—withitscorrespondingnormalcontrol.IndelanalysiswasperformedusingGATKaccordingtobestpractices.Somaticeventsonly,i.e.,presentinthetumorbutnotinthematch-ingcontrols,arethenre nedbydepthofcoverage,variantallelefrequencyinthetumor,andcontrolto lteroutlowqualitycalls.The nallistisconvertedintoaMAF leformat.
QueryofmutationsinotherprostatecancerdatasetswasdonethroughtheMSKCCcomputationalbiologyportal(doc.guandang.net)(Ceramietal.,2012).
CellViabilityandProliferationAssay
Cellviabilityassayswereconductedbyplating5,000organoidscellsperwellofacollagencoated96-wellcellcultureplatein100mlcompletehumanmediawith0.1nMDHTandtreatedwithvehicle(DMSO)controlorenzalutamide(0.01–500nM),everolimus(0.25–50nM),BKM120(0.05–5mM).ViablecellswerecountedusingaCellTiter-Glo(Promega)LuminescentCellViabilityAssay.Allcellviabilityexperimentswereconductedinquadruplicateandstan-darddeviationswerereported.
XenograftStudies
AllmouseexperimentswasperformedunderMSKCCIACUCapprovedproto-col.Forsubcutaneousgrowth,2–4millioncellsweremixed50:50withMatrigelandinjectedintomiceCB17SCIDmice.Forrenalcapsulegrowth,100KcellsweremixedintocollagenplugandimplantedundertherenalcapsuleofCB17SCIDmice.
Drugtreatmentwasstartedwhentumorsreached500mm3.Everolimus(Novartis)wasdissolvedinwateranddosedat10mg/kgdose5daysperweek.Enzalutamidewasdissolvedinvehicle(1%carboxymethylcellulose,0.1%Tween-80,5%DMSO)andusedat10mg/kgdosed5daysperweek.Tumorssizewasmeasuredtwiceweeklyorweeklydependingongrowthrate.
Repositories
TheorganoidlineswillbedistributedbyMSKCCincompliancetotheIRB-approvedinformedconsentsignedbythepatient.Geneticsdatafromar-ray-CGH,RNA-seq,andwhole-exomesequencingcanbeanalyzedanddownloadedfromtheMSKCCcBioportal(doc.guandang.net)(Ceramietal.,2012).
10Cell159,1–12,September25,2014ª2014Elsevier

Inc.
ACCESSIONNUMBERS
TheGEOaccessionforthearray-CGHdatareportedinthispaperisGSE60612.
SUPPLEMENTALINFORMATION
SupplementalInformationincludesExtendedExperimentalProcedures, ve gures,andthreetablesandcanbefoundwiththisarticleonlineatdoc.guandang.net
D.G.,I.V.,P.J.I.,andC.D.performedisolation,characterization,andgrowthofthehumanorganoids.A.S.andS.R.performedintegrativegenomicsanalysis.B.C.,W.R.K.,M.A.R.,H.I.S.,H.C.,C.L.S.,andY.C.conceivedandoversawtheproject.A.G.andJ.-M.M.performedpathologicevaluation.J.N.W.,M.K.,T.Y.M.,E.A.U.,L.P.B.,W.D.,Z.C.,Q.F.Z.,I.S.,andL.R.helpedwithexperi-mentsandprovidedtechnicalsupport.J.W.performedmousexenograftexperiments.H.B.,V.K.A.,J.A.E.,K.A.T.,P.T.S.,V.P.L.assessed,obtainedconsent,andacquiredsurgicalpatienttissues.D.E.R.,M.J.M.,D.C.D.,S.F.S.,andH.I.S.assessed,andobtainedconsentfrompatientsforbiopsyspecimens.S.B.S.assessedpatientsforbiopsysiteselectionandperformedbiopsies.K.R.C.istheresearchprojectcoordinatorwhotrackedclinicalinfor-mationandcoordinatedresearchbiopsies.P.C.andH.B.providedintellectualinput.Y.C.andC.L.S.wrotethemanuscriptandH.I.S.,M.A.R.andA.S.pro-vidededitorialinput.ACKNOWLEDGMENTS
WewouldliketothanktheProstateCancerFoundation(PCF)forgenerous nancialsupportaswellasDrs.HowardSouleandJonathonSimonsforstim-ulatingdiscussions.WethankthefollowMSKCCcorefacilities:GenomicsCoreLaboratory(DaoqiYou,AgnesViales),andMolecularCytology(NingFanandMesruhTurkekul).WethanktheNationalInstitutesofHealth(5K08CA140946,Y.C.;P50CA092629Y.C.,H.I.S.,B.C.,C.L.S.;CA155169-01A1,C.L.S.;5R01CA116337,H.B.andM.A.R.),USDepartmentofDefense(W81XWH-10-1-0197,Y.C.;W81XWH-09-1-0147,H.I.S.),MovemberFounda-tion(Y.C.,D.C.D.,B.C.,S.B.S.,C.L.S.),theGeoffreyBeeneCancerCenter(Y.C.,B.C.)theSTARRCancerConsortiumforfunding(I8-A722,Y.C.,H.B.,M.A.R.).ResearchsupportedbyaStandUpToCancer–ProstateCancerFoundationProstateDreamTeamTranslationalResearchGrant(SU2C-AACR-DT0712).StandUpToCancerisaprogramoftheEntertainmentIndus-tryFoundationadministeredbytheAmericanAssociationforCancerResearch.H.C.isaninventoronseveralparentsrelatedtothiswork.Received:April14,2014Revised:July22,2014
Accepted:August12,2014Published:September4,2014REFERENCES
Arora,V.K.,Schenkein,E.,Murali,R.,Subudhi,S.K.,Wongvipat,J.,Balbas,M.D.,Shah,N.,Cai,L.,Efstathiou,E.,Logothetis,C.,etal.(2013).Glucocorti-coidreceptorconfersresistancetoantiandrogensbybypassingandrogenreceptorblockade.Cell155,1309–1322.
Baca,S.C.,Prandi,D.,Lawrence,M.S.,Mosquera,J.M.,Romanel,A.,Drier,Y.,Park,K.,Kitabayashi,N.,MacDonald,T.Y.,Ghandi,M.,etal.(2013).Punc-tuatedevolutionofprostatecancergenomes.Cell153,666–677.
Balbas,M.D.,Evans,M.J.,Hos eld,D.J.,Wongvipat,J.,Arora,V.K.,Watson,P.A.,Chen,Y.,Greene,G.L.,Shen,Y.,andSawyers,C.L.(2013).Overcomingmutation-basedresistancetoantiandrogenswithrationaldrugdesign.eLife2,e00499.
Barbieri,C.E.,Baca,S.C.,Lawrence,M.S.,Demichelis,F.,Blattner,M.,Theur-illat,J.P.,White,T.A.,Stojanov,P.,VanAllen,E.,Stransky,N.,etal.(2012).
from patients with advanced prostate, bladder, or breast cancer as well as...Regardless of whether the peptidome is derived from the tissue/microenvironment...
[6], advanced melanoma [11], prostate cancer [...from healthy donors and from patients with chronic...In DC cultures of four healthy donors, Freezing ...
热门文档